Insider Trading Alert - AMRI, CHE And LXK Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, April 2, 2014, 123 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $278.57 to $71,423,275.14.

Highlighted Stocks Traded by Insiders:

Albany Molecular Research (AMRI) - FREE Research Report

Henderson Lori M who is VP, Secretary & Gen. Counsel at Albany Molecular Research sold 2,500 shares at $18.74 on April 2, 2014. Following this transaction, the VP, Secretary & Gen. Counsel owned 56,497 shares meaning that the stake was reduced by 4.24% with the 2,500-share transaction.

Cable Stuart M who is 10% Owner at Albany Molecular Research sold 30,000 shares at $18.52 on April 2, 2014. Following this transaction, the 10% Owner owned 4.3 million shares meaning that the stake was reduced by 0.69% with the 30,000-share transaction.

The shares most recently traded at $17.21, down $1.31, or 7.61% since the insider transaction. Historical insider transactions for Albany Molecular Research go as follows:

  • 4-Week # shares bought: 30,000
  • 4-Week # shares sold: 1,500
  • 12-Week # shares bought: 30,000
  • 12-Week # shares sold: 3,000
  • 24-Week # shares bought: 50,000
  • 24-Week # shares sold: 5,300

The average volume for Albany Molecular Research has been 618,600 shares per day over the past 30 days. Albany Molecular Research has a market cap of $597.7 million and is part of the health care sector and drugs industry. Shares are up 76.49% year-to-date as of the close of trading on Wednesday.

Albany Molecular Research, Inc., a contract research and manufacturing company, provides integrated drug discovery, development, and manufacturing services primarily in the United States, Europe, and Asia. The company has a P/E ratio of 48.9. Currently there are no analysts that rate Albany Molecular Research a buy, 1 analyst rates it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on AMRI - FREE

TheStreet Quant Ratings rates Albany Molecular Research as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, largely solid financial position with reasonable debt levels by most measures and reasonable valuation levels. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full Albany Molecular Research Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Chemed Corporation (CHE) - FREE Research Report

Lee Spencer S who is executive vice president at Chemed Corporation sold 2,000 shares at $90.15 on April 2, 2014. Following this transaction, the executive vice president owned 65,848 shares meaning that the stake was reduced by 2.95% with the 2,000-share transaction.

The shares most recently traded at $91.13, up $0.98, or 1.08% since the insider transaction. Historical insider transactions for Chemed Corporation go as follows:

  • 4-Week # shares sold: 7,375
  • 12-Week # shares sold: 19,836
  • 24-Week # shares sold: 47,022

The average volume for Chemed Corporation has been 297,400 shares per day over the past 30 days. Chemed Corporation has a market cap of $1.6 billion and is part of the health care sector and health services industry. Shares are up 18.6% year-to-date as of the close of trading on Wednesday.

Chemed Corporation provides hospice and palliative care services in the United States. It operates in two segments, VITAS and Roto-Rooter. The company offers its services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers. The stock currently has a dividend yield of 0.91%. The company has a P/E ratio of 21.2. Currently there is 1 analyst that rates Chemed Corporation a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on CHE - FREE

TheStreet Quant Ratings rates Chemed Corporation as a buy. The company's strengths can be seen in multiple areas, such as its increase in stock price during the past year, largely solid financial position with reasonable debt levels by most measures and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Chemed Corporation Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Lexmark International (LXK) - FREE Research Report

Hardis Stephen R who is Director at Lexmark International bought 537 shares at $46.45 on April 2, 2014. Following this transaction, the Director owned 100,441 shares meaning that the stake was reduced by 0.54% with the 537-share transaction.

The shares most recently traded at $47.67, up $1.22, or 2.56% since the insider transaction. Historical insider transactions for Lexmark International go as follows:

  • 4-Week # shares bought: 675
  • 4-Week # shares sold: 78,674
  • 12-Week # shares bought: 675
  • 12-Week # shares sold: 85,890
  • 24-Week # shares bought: 675
  • 24-Week # shares sold: 85,890

The average volume for Lexmark International has been 1.1 million shares per day over the past 30 days. Lexmark International has a market cap of $2.9 billion and is part of the technology sector and computer hardware industry. Shares are up 33.25% year-to-date as of the close of trading on Wednesday.

Lexmark International, Inc., together with its subsidiaries, operates as a developer, manufacturer, and supplier of printing, imaging, device management, managed print services (MPS), document workflow, and business process and content management solutions worldwide. The stock currently has a dividend yield of 2.7%. The company has a P/E ratio of 10.9. Currently there are no analysts that rate Lexmark International a buy, 3 analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on LXK - FREE

TheStreet Quant Ratings rates Lexmark International as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, compelling growth in net income, revenue growth, attractive valuation levels and good cash flow from operations. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Lexmark International Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.
null

If you liked this article you might like

EY's Greene Sees More Med Tech, CRO Deals Ahead

EY's Greene Sees More Med Tech, CRO Deals Ahead

Biotech Movers: Albany Molecular Shares Soar on Sale to PE Firms

Biotech Movers: Albany Molecular Shares Soar on Sale to PE Firms

Albany Molecular Research (AMRI) Is Weak On High Volume Today

Albany Molecular Research (AMRI) Is Weak On High Volume Today

Insider Trading Alert - MGRC, GUID And AMRI Traded By Insiders

Insider Trading Alert - MGRC, GUID And AMRI Traded By Insiders

Insider Trading Alert - NTGR, SCOR And AMRI Traded By Insiders

Insider Trading Alert - NTGR, SCOR And AMRI Traded By Insiders